Volume 24, Issue 104, July - August, 2020

Comparing efficacy of zoledronic acid administration at different intervals regarding quality of life and pain control in the treatment of metastatic bone disease patients

Ebtisam Ragab Qasem^♦, Yousra Taha Dorgham, Seham Mohammed Elhagrasy, Nashwa Elsayed Nawar

Clinical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt, Email: EbtisamRagab222@gmail.com

^♦Corresponding author
Clinical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt, Email: EbtisamRagab222@gmail.com

ABSTRACT

Background: Bone is ranking the third frequent site of metastasis. Bone metastatic disease may strongly harm a patient's quality of life. Patients receive Zoledronic acid in order to decrease skeletal-related events and pain. Aim: evaluating the efficacy of Zoledronic given every ’twelve weeks’ regimen versus ’four weeks’ regimen. It is given every four weeks’ regimen in management of patient with bone metastasis. Patients and Methods: The study is a randomized, clinical trial conducted at university of Zagazig hospitals from February 2018 to February 2020. 108 Patients were enrolled in this study to dose Zoledronic (A and B groups=12 and 4 weeks, respectively) for 2 years. Results: Post-treatment skeletal related events had occurred in 18.5% of group A versus 14.8% of group B (p-value=0.935). There was an insignificant difference between group A and group B regarding pre-treatment ECOG performance status, pain severity and analgesia type and opioid dose. There was also an insignificant difference between both groups regarding post-treatment ECOG performance status, pain severity and analgesia type and opioid dose. There was a significant improvement of ECOG performance status after intervention within each group. Pain severity had significantly decreased among both groups with a significant decrease in opioid usage and opioid dose. Conclusion: The Zoledronic regimen given for 3 months was not inferior to the regimen of Zoledronic doses monthly in controlling pain and improving quality of life of patients in prostate, breast cancers and, multiple myeloma.

Keywords: Zoledronic, Efficacy, Bone metastasis

Medical Science, 2020, 24(104), 2494-2503

PDF